• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肥厚型心肌病中心律失常与 MYH7 肌球蛋白重链基因突变相关。

Incident Atrial Fibrillation Is Associated With MYH7 Sarcomeric Gene Variation in Hypertrophic Cardiomyopathy.

机构信息

Division of Cardiovascular Medicine, Department of Medicine, Stanford University, CA (S.-P.L., E.A.A., M.V.P.).

Department of Internal Medicine, Seoul National University Hospital, South Korea (S.-P.L.).

出版信息

Circ Heart Fail. 2018 Sep;11(9):e005191. doi: 10.1161/CIRCHEARTFAILURE.118.005191.

DOI:10.1161/CIRCHEARTFAILURE.118.005191
PMID:30354366
Abstract

Background Although atrial fibrillation (AF) is common in hypertrophic cardiomyopathy (HCM) patients, the relationship between genetic variation and AF has been poorly defined. Characterizing genetic subtypes of HCM and their associations with AF may help to improve personalized medical care. We aimed to investigate the link between sarcomeric gene variation and incident AF in HCM patients. Methods and Results Patients from the multinational Sarcomeric Human Cardiomyopathy Registry were followed for incident AF. Those with likely pathogenic or pathogenic variants in sarcomeric genes were included. The AF incidence was ascertained by review of medical records and electrocardiograms at each investigative site. One thousand forty adult HCM patients, without baseline AF and with likely pathogenic or pathogenic variation in either MYH7 (n=296), MYBPC3 (n=659), or thin filament genes (n=85), were included. Compared with patients with variation in other sarcomeric genes, those with MYH7 variants were younger on first clinical encounter at the Sarcomeric Human Cardiomyopathy Registry site and more likely to be probands than the MYBPC3 variants. During an average follow-up of 7.2 years, 198 incident AF events occurred. Patients with likely pathogenic or pathogenic mutations in MYH7 had the highest incidence of AF after adjusting for age, sex, proband status, left atrial size, maximal wall thickness, and peak pressure gradient (hazard ratio, 1.7; 95% CI, 1.1-2.6; P=0.009). Conclusions During a mean follow-up of 7.2 years, new-onset AF developed in 19% of HCM patients with sarcomeric mutations. Compared with other sarcomeric genes, patients with likely pathogenic or pathogenic variation in MYH7 had a higher rate of incident AF independent of clinical and echocardiographic factors.

摘要

背景 尽管心房颤动(AF)在肥厚型心肌病(HCM)患者中很常见,但遗传变异与 AF 之间的关系尚未得到明确界定。描述 HCM 的遗传亚型及其与 AF 的关联可能有助于改善个性化医疗。我们旨在研究 HCM 患者中肌节基因突变与 AF 事件之间的关系。

方法和结果 来自多国肌节性人类心肌病注册处的患者接受了 AF 事件的随访。那些在肌节基因中存在可能致病或致病性变异的患者被包括在内。每个研究地点通过审查病历和心电图来确定 AF 发生率。纳入了 1040 名成年 HCM 患者,这些患者无基线 AF,并且在肌球蛋白重链(MYH7)(n=296)、肌球蛋白结合蛋白 C(MYBPC3)(n=659)或细肌丝基因(n=85)中存在可能致病或致病性变异。与其他肌节基因变异的患者相比,在肌球蛋白重链基因变异的患者中,在首次就诊于肌节性人类心肌病注册处时年龄较轻,并且更有可能是先证者,而不是 MYBPC3 变异的先证者。在平均 7.2 年的随访期间,发生了 198 例 AF 事件。在调整年龄、性别、先证者状态、左心房大小、最大壁厚度和峰值压力梯度后,在 MYH7 中存在可能致病或致病性突变的患者的 AF 发生率最高(危险比,1.7;95%CI,1.1-2.6;P=0.009)。

结论 在平均 7.2 年的随访期间,19%的肌节突变 HCM 患者新发 AF。与其他肌节基因相比,MYH7 中存在可能致病或致病性变异的患者发生 AF 的发生率更高,独立于临床和超声心动图因素。

相似文献

1
Incident Atrial Fibrillation Is Associated With MYH7 Sarcomeric Gene Variation in Hypertrophic Cardiomyopathy.肥厚型心肌病中心律失常与 MYH7 肌球蛋白重链基因突变相关。
Circ Heart Fail. 2018 Sep;11(9):e005191. doi: 10.1161/CIRCHEARTFAILURE.118.005191.
2
Myocardial Deformation Analysis in and Related Sarcomeric Hypertrophic Cardiomyopathy-The Graz Hypertrophic Cardiomyopathy Registry.心肌变形分析与相关肌节肥厚型心肌病——格拉茨肥厚型心肌病注册研究。
Genes (Basel). 2021 Sep 23;12(10):1469. doi: 10.3390/genes12101469.
3
Presence of Hypertrophic Cardiomyopathy Related Gene Mutations and Clinical Manifestations in Vietnamese Patients With Hypertrophic Cardiomyopathy.肥厚型心肌病相关基因突变的存在与越南肥厚型心肌病患者的临床表现。
Circ J. 2019 Aug 23;83(9):1908-1916. doi: 10.1253/circj.CJ-19-0190. Epub 2019 Jul 12.
4
Long-Term Prevalence of Systolic Dysfunction in MYBPC3 Versus MYH7-Related Hypertrophic Cardiomyopathy.MYBPC3 相关肥厚型心肌病与 MYH7 相关肥厚型心肌病患者的收缩功能障碍长期患病率。
Circ Genom Precis Med. 2023 Aug;16(4):363-371. doi: 10.1161/CIRCGEN.122.003832. Epub 2023 Jul 6.
5
Clinical outcomes associated with sarcomere mutations in hypertrophic cardiomyopathy: a meta-analysis on 7675 individuals.肥厚型心肌病中与肌节突变相关的临床结局:对 7675 个人的荟萃分析。
Clin Res Cardiol. 2018 Jan;107(1):30-41. doi: 10.1007/s00392-017-1155-5. Epub 2017 Aug 24.
6
Association of variants in MYH7, MYBPC3 and TNNT2 with sudden cardiac death-related risk factors in Brazilian patients with hypertrophic cardiomyopathy.MYH7、MYBPC3 和 TNNT2 变异与巴西肥厚型心肌病患者与心源性猝死相关危险因素的关联。
Forensic Sci Int Genet. 2021 May;52:102478. doi: 10.1016/j.fsigen.2021.102478. Epub 2021 Feb 3.
7
Unexpectedly low mutation rates in beta-myosin heavy chain and cardiac myosin binding protein genes in Italian patients with hypertrophic cardiomyopathy.意大利肥厚型心肌病患者的β-肌球蛋白重链和心肌肌球蛋白结合蛋白基因突变率出人意料地低。
J Cell Physiol. 2011 Nov;226(11):2894-900. doi: 10.1002/jcp.22636.
8
Atrial Fibrillation Substrate and Catheter Ablation Outcomes in MYBPC3- and MYH7-Mediated Hypertrophic Cardiomyopathy.MYBPC3- 和 MYH7 介导的肥厚型心肌病中心房颤动基质和导管消融的结果。
JACC Clin Electrophysiol. 2024 Jul;10(7 Pt 1):1380-1391. doi: 10.1016/j.jacep.2024.03.026. Epub 2024 May 29.
9
Prevalence and Phenotypic Expression of Mutations in the MYH7, MYBPC3 and TNNT2 Genes in Families with Hypertrophic Cardiomyopathy in the South of Brazil: A Cross-Sectional Study.巴西南部肥厚型心肌病家族中MYH7、MYBPC3和TNNT2基因突变的患病率及表型表达:一项横断面研究
Arq Bras Cardiol. 2016 Sep;107(3):257-265. doi: 10.5935/abc.20160133.
10
Genetic determinants of clinical phenotype in hypertrophic cardiomyopathy.肥厚型心肌病临床表型的遗传决定因素。
BMC Cardiovasc Disord. 2020 Dec 9;20(1):516. doi: 10.1186/s12872-020-01807-4.

引用本文的文献

1
Reduced TBX5 dosage undermines developmental control of atrial cardiomyocyte identity in a model of human atrial disease.在人类心房疾病模型中,TBX5剂量减少会破坏心房心肌细胞特性的发育控制。
bioRxiv. 2025 Aug 19:2025.08.16.669546. doi: 10.1101/2025.08.16.669546.
2
Atrial fibrillation and thromboembolic risk in hypertrophic cardiomyopathy.肥厚型心肌病中的心房颤动与血栓栓塞风险
J Cardiovasc Imaging. 2025 Aug 25;33(1):12. doi: 10.1186/s44348-025-00057-2.
3
Atrial remodelling and dysfunction in hypertrophic cardiomyopathy: prognostic role and therapeutic target.
肥厚型心肌病中的心房重构与功能障碍:预后作用及治疗靶点
Front Cardiovasc Med. 2025 Jul 8;12:1620313. doi: 10.3389/fcvm.2025.1620313. eCollection 2025.
4
Genetic insights into hypertrophic cardiomyopathy: pathogenesis, diagnosis, and therapeutic implications.肥厚型心肌病的遗传学见解:发病机制、诊断及治疗意义
J Cardiovasc Imaging. 2025 Jul 21;33(1):9. doi: 10.1186/s44348-025-00055-4.
5
External validation of atrial fibrillation risk prediction tools in a racially diverse cohort of patients with hypertrophic cardiomyopathy.肥厚型心肌病患者种族多样化队列中心房颤动风险预测工具的外部验证
Heart Rhythm. 2025 May 23. doi: 10.1016/j.hrthm.2025.05.046.
6
Atrial Fibrillation Induces Sarcomere Remodeling, Enhanced Sarcomere Contractility, and Loss of Atrial Identity.心房颤动会导致肌节重塑、肌节收缩力增强以及心房特性丧失。
Res Sq. 2025 Apr 23:rs.3.rs-6422874. doi: 10.21203/rs.3.rs-6422874/v1.
7
MYH7 Mutations in Restrictive Cardiomyopathy.限制型心肌病中的MYH7突变
JACC Adv. 2025 May;4(5):101693. doi: 10.1016/j.jacadv.2025.101693. Epub 2025 Apr 25.
8
Exploring the Current Status of Risk Stratification in Hypertrophic Cardiomyopathy: From Risk Models to Promising Techniques.探索肥厚型心肌病风险分层的现状:从风险模型到有前景的技术。
J Cardiovasc Dev Dis. 2025 Mar 14;12(3):101. doi: 10.3390/jcdd12030101.
9
Genetic and Molecular Underpinnings of Atrial Fibrillation.心房颤动的遗传和分子基础
NPJ Cardiovasc Health. 2024;1. doi: 10.1038/s44325-024-00035-5. Epub 2024 Dec 4.
10
Pathogenic genes and clinical prognosis in hypertrophic cardiomyopathy.肥厚型心肌病的致病基因与临床预后
World J Cardiol. 2025 Jan 26;17(1):99595. doi: 10.4330/wjc.v17.i1.99595.